The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -69,707 | -63,018 | -167,303 | - |
| Depreciation and amortization | 845 | 751 | 745 | 1,120 |
| Share-based compensation expense | 13,355 | 3,590 | 3,709 | 5,599 |
| Net periodic pension benefit gain (loss) for the qualified pension plan | 11 | -31 | -18 | -9 |
| Other non-cash items | -422 | 92 | -283 | 1,211 |
| Other receivables | 894 | 847 | 612 | 566 |
| Operating lease right-of-use assets | 30 | 0 | 0 | 0 |
| Prepaid expenses | 10,100 | -3,857 | -274 | 3,570 |
| Other non-current assets | 749 | 0 | -1,110 | 1,697 |
| Trade and other payables | -6,173 | 4,270 | 8,203 | 8,087 |
| Operating lease liabilities | -389 | -377 | -401 | -444 |
| Accrued expenses and other current liabilities | 7,123 | -6,897 | 12,856 | -3,368 |
| Net cash flow used in operating activities | -66,286 | -58,794 | -44,543 | -92,670 |
| Purchase of short-term marketable debt securities | 59,068 | 59,167 | 0 | 206,207 |
| Proceeds from maturities of short-term marketable debt securities | 59,166 | 29,256 | 88,403 | 350,742 |
| Purchase of property and equipment | 0 | 0 | 0 | 35 |
| Net cash flow provided by investing activities | 98 | -29,911 | 88,403 | 144,500 |
| Proceeds from options exercised under esop | - | - | - | 100 |
| Proceeds from long-term debt, net of issuance costs | 24,467 | 0 | 0 | 73,022 |
| Issuance of class a ordinary shares, net of transaction costs | 6,007 | 72,395 | 0 | 0 |
| Stamp duty on capital injection from moonlake to moonlake ag | - | 0 | 0 | 0 |
| Proceeds from options exercised-Equity Incentive Plan | 170 | 0 | 480 | - |
| Proceeds from options exercised-Employee Stock Option Plan ESOP | 0 | 0 | 100 | - |
| Net cash flow provided by financing activities | 30,644 | 72,395 | 480 | 73,122 |
| Effect of movements in exchange rates on cash held | -483 | 91 | -285 | 1,303 |
| Net change in cash and cash equivalents | -36,027 | -16,219 | 44,055 | 126,255 |
| Cash and cash equivalents, beginning of period | 334,517 | 350,736 | 180,426 | - |
| Cash and cash equivalents, end of period | 298,490 | 334,517 | 350,736 | - |
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)